Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Aliskiren Hemifumarate Patent Expiration

Aliskiren Hemifumarate is Used for treating high blood pressure. It was first introduced by Noden Pharma Dac in its drug Tekturna on Mar 5, 2007. 2 different companies have introduced drugs containing Aliskiren Hemifumarate.


Aliskiren Hemifumarate Patents

Given below is the list of patents protecting Aliskiren Hemifumarate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tekturna US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides Jul 21, 2018

(Expired)

 Noden Pharma
Tekturna US5559111

(Pediatric)

 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides Jan 21, 2019

(Expired)

 Noden Pharma
Tekturna US8617595 Galenic formulations of organic compounds Feb 19, 2026 Noden Pharma
Tekturna US8617595

(Pediatric)

 Galenic formulations of organic compounds Aug 19, 2026 Noden Pharma


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aliskiren Hemifumarate's patents.

Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 16 Jun, 2021 US8617595
Post Issue Communication - Certificate of Correction 23 Mar, 2015 US8617595
Email Notification 21 Jan, 2015 US8617595
Mail-Petition Decision - Dismissed 13 Jan, 2015 US8617595
Petition Decision - Dismissed 12 Jan, 2015 US8617595
Adjustment of PTA Calculation by PTO 05 Jan, 2015 US8617595
Petition Entered 23 Jan, 2014 US8617595
Recordation of Patent Grant Mailed 31 Dec, 2013 US8617595
Patent Issue Date Used in PTA Calculation 31 Dec, 2013 US8617595
Email Notification 12 Dec, 2013 US8617595



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Aliskiren Hemifumarate Generics

Several generic applications have been filed for Aliskiren Hemifumarate.

Given below is the list of companies who have filed for Aliskiren Hemifumarate generic.


1. ENDO OPERATIONS

Endo Operations Ltd has filed for 2 different strengths of generic version for Aliskiren Hemifumarate. Given below are the details of the strengths of this generic introduced by Endo Operations.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Prescription ORAL AB Mar 22, 2019
EQ 300MG BASE tablet Prescription ORAL AB Mar 22, 2019